The Man Who Never Has a Down Year Is Still Holding This One
In a world drowning in health data and drowning in healthcare costs, the most valuable thing you can do is find disease earlier. Not treat it later. Find it earlier.
That single insight is worth hundreds of billions of dollars. It is also the foundation of the thesis I want to talk to you about today.
Cancer kills approximately 10 million people globally every year. The overwhelming majority of those deaths are not caused by cancers that cannot be treated. They are caused by cancers that were not found early enough. The difference between stage one and stage four is not medical capability. It is timing. It is information. It is a blood test that tells you what your body already knows before you feel any symptoms at all.
One company has built the most validated, most reimbursed, most clinically deployed platform for doing exactly that. It just reported full-year 2025 revenue of $2.31 billion, growing at 40% year over year in the final quarter. It has $1.08 billion in cash, essentially no debt, and is now generating positive operating cash flow. Stanley Druckenmiller, the man who ran George Soros’s Quantum Fund for 14 years without a single down year and averaged 30% annual returns across his career, has held this company as his largest disclosed position for multiple years running.
I have covered Natera ($NTRA) before. I am covering it again because the story has materially advanced and the market has not fully priced what is now in front of us.
Why Natera ($NTRA) Now
The convergence of artificial intelligence and genomics is creating a category that did not exist a decade ago: real-time, ultra-sensitive molecular surveillance of disease inside the human body. Not imaging. Not symptom-based diagnosis. Molecular signals detected in a blood sample before clinical manifestations appear.
Western healthcare systems are under profound strain. Aging populations, rising chronic disease prevalence, overwhelmed oncology departments, and the staggering economic cost of late-stage disease treatment are pushing governments and insurers toward one unavoidable conclusion: early detection is not just better medicine, it is dramatically cheaper medicine. A stage one colorectal cancer costs roughly $30,000 to treat. A stage four metastatic case can cost ten times that with far worse outcomes. The economic logic of early detection is as compelling as the humanitarian one.
Natera sits at the exact intersection of this urgency. Its Signatera test uses circulating tumor DNA extracted from a patient’s blood to detect and quantify residual cancer with extraordinary precision. Its Panorama test is the leading platform for non-invasive prenatal genetic testing. Its Prospera test monitors organ rejection in transplant patients. Together these three platforms address some of the highest-stakes diagnostic moments in medicine.
This is not speculative science. It is deployed clinical infrastructure with Medicare reimbursement, over 350 peer-reviewed publications, and more than 100 specific clinical validation studies for Signatera alone.
Skin in the Game and the Druckenmiller Signal
Stanley Druckenmiller first bought Natera in the third quarter of 2022, when the stock was trading sideways and most investors had moved on. He built the position patiently as the stock found its footing. As NTRA began to break out, he kept adding. His Duquesne Family Office held 2.51 million shares as of the most recent data available, representing approximately 12.94% of his disclosed portfolio and a stake worth roughly $517 million at recent prices. This is his largest position.
This matters for a specific reason. Druckenmiller runs a family office. He invests only his own capital. There are no client pressures, no marketing considerations, no benchmark-hugging incentives. When he holds something as his top position for multiple years and keeps buying dips, he believes in the thesis at the deepest level of personal financial conviction. He was early on NVIDIA before the AI wave. He was early on Meta before the rebound. He built his Natera position before it had a 440% run from 2023 to 2025. Despite trimming modestly in 2025, Natera remains his largest holding as of Q4 2025 by a wide margin.
That is not a footnote. That is a signal.
Management Skill
Steve Chapman, Natera’s CEO, took over the company and has presided over an extraordinary period of commercial execution. The financial trajectory under his leadership speaks clearly: Q4 2025 revenue of $665.5 million represents a 39.8% year-over-year increase. Full-year 2025 gross margin reached approximately 64.9%, up meaningfully from 61.8% in the prior year. The company generated $107.6 million in positive cash inflow for the full year. Days Sales Outstanding improved from 68 days to 47 days in Q4 2025 alone, suggesting significant improvement in revenue cycle management and payer relationships.
The 2026 guidance issued in February 2026 projects revenue of $2.62-2.70 billion with gross margin of 63%-65% and continued positive cash generation. That is a company executing with discipline, expanding margins while investing aggressively in clinical development and market access.
The acquisition of Foresight Diagnostics in December 2025 is a strategic move that deserves attention. Foresight’s phased variant technology can detect cancer below 1 part per 10 million sensitivity, extending Signatera’s already leading performance into an even more ultra-sensitive regime. This expanded platform is now available for biopharma research use and is expected to launch clinically in 2026. It also brings leadership in lymphoma MRD testing, a large and underserved market.
Industry Overview and Category-Defining Potential
The minimal residual disease testing market is still in its early innings. Clinical MRD volumes for Natera’s oncology products hit approximately 225,000 tests in Q4 2025 alone, growing 56% year over year. The acceleration across multiple tumor types reflects both clinical adoption and the compounding effect of reimbursement decisions that make these tests financially accessible to patients.
The reimbursement story is the most important commercial development in the Natera narrative this year. Medicare coverage for Signatera Genome was confirmed in June 2025 under LCD L38779, covering Medicare beneficiaries with colorectal, breast, bladder, ovarian, and lung cancers, as well as pan-cancer immunotherapy monitoring. Medicare coverage is the gateway to broad clinical adoption. Physicians who hesitated to order a test without reimbursement confidence now have that confidence.
Beyond MRD, Natera filed a Pre-Market Approval application with the FDA for Signatera as a companion diagnostic in muscle-invasive bladder cancer, supported by results from the IMvigor011 trial published in the New England Journal of Medicine in October 2025 and featured at the ESMO Presidential Symposium. If approved, Signatera CDx would be the first companion diagnostic to guide adjuvant immunotherapy decisions in this indication. That is a regulatory milestone that would unlock a new commercial channel and validate Natera’s platform at the highest level of clinical evidence.
Signatera also holds three FDA Breakthrough Device Designations, each supporting accelerated approval pathways and expedited reimbursement consideration. These are not promotional labels. They are regulatory determinations that the technology addresses unmet medical needs in life-threatening conditions.
Moat and Durability
Natera’s competitive moat has three reinforcing layers that compound over time.
The first is clinical validation depth. Over 350 peer-reviewed publications supporting Natera’s tests is not something a competitor can replicate quickly. Clinical validation takes years, requires thousands of patients, and must be replicated across tumor types and treatment settings. Each published study reinforces Natera’s position as the gold standard, generates physician awareness, and provides the evidence base that payers require for coverage decisions.
The second is reimbursement infrastructure. Medicare and commercial payer coverage decisions are hard-won and cumulative. Natera has spent years building the clinical and health economic evidence that supports favorable reimbursement. A new entrant faces not just a science challenge but a multi-year payer engagement challenge that Natera has already navigated.
The third is biopharma partnerships. Natera is deeply embedded in pharmaceutical clinical trials as the preferred MRD testing platform for measuring treatment response. Over 75,000 patients are currently enrolled in prospective clinical trials using Signatera. Each trial generates additional validation data, creates new commercial channels when drugs are approved, and deepens Natera’s position as the infrastructure layer of precision oncology. These relationships are not easily displaced.
The timing dimension is also critical. The clinical evidence is reaching a tipping point. The Medicare coverage is now in place. The FDA companion diagnostic pathway is active. The phased variant technology is coming to clinical use in 2026. The window of maximum adoption is opening now, and the companies with established positions at this moment will be structurally advantaged for the next decade.
Current Market Cap and Upside Potential
Natera currently trades at approximately $197 per share with a market cap of approximately $28 billion and trailing twelve-month revenue of $2.31 billion. The stock trades at roughly 12x trailing revenue, which is a meaningful premium to the broad market. This is not a value stock.
The bull case, however, does not require heroic assumptions. It requires the following: first, that revenue continues growing at a high-teens to low-twenties percentage rate toward $4-5 billion over the next three to four years; second, that gross margins continue expanding toward 70% as scale, automation, and improved reimbursement rates compound; and third, that the company achieves operating profitability on the trajectory management has outlined, with EPS consensus currently projecting positive earnings by 2028.
A $5 billion revenue business with 70% gross margins and operating leverage comparable to what we have already seen in the trajectory is a business worth $40-60 billion at reasonable multiples. That is 40-100% upside from today’s market cap on a three to four year horizon, without requiring anything to go particularly right. The FDA approvals, additional reimbursement expansions, and international market penetration are not priced into those numbers. They represent the upside scenario.
The oncology personalization thesis is the most important structural theme in healthcare for the next decade. Natera is the category leader.
Risk
I will not understate the risks because this is FJ Research and we do not do promotional analysis.
The valuation demands execution. At 12x revenue the stock has no margin for error on a quarterly basis. A miss on revenue guidance, a delay in an FDA approval, or an adverse coverage decision from CMS would move the stock violently to the downside. The stock is not cheap. It is priced for continued excellence.
The company is not yet operating-income profitable on a GAAP basis. It generated positive cash flow in 2025, which is a meaningful inflection, but the path to sustained net income profitability requires continued revenue growth and SG&A leverage as the commercial infrastructure matures. That path is visible and credible, but it is not yet delivered.
Reimbursement risk is real and ongoing. CMS coverage decisions can be modified. Private payer reimbursement rates are subject to renegotiation. Any adverse movement in the reimbursement environment would affect both revenue recognition and commercial adoption rates.
The approach here, as I have said before, is invest then investigate. The weight of evidence from the clinical data, the reimbursement milestones, the management execution, and the Druckenmiller signal all point in the same direction. The risks are real but they are the risks of a category leader in a category that is growing structurally. They are not existential risks. They are execution risks, and this management team has consistently demonstrated the ability to execute.
The Verdict
Cancer is the defining healthcare challenge of our era. Early detection is the lever that changes outcomes most dramatically. Natera has built the most validated, most reimbursed, most clinically embedded platform for detecting molecular residual disease in cancer patients anywhere in the world.
The commercial inflection has happened. The cash flow inflection has happened. The reimbursement foundation is in place. The FDA companion diagnostic pathway is active. The acquisition of Foresight adds the next generation of sensitivity. The biopharma trial infrastructure is deepening every quarter.
Stanley Druckenmiller still holds this as his largest position after a 440% run. That is worth understanding. He does not hold positions out of inertia. He holds them because the thesis continues to develop.
This is not the beginning of the Natera story. But it is very likely the beginning of the decade in which Natera becomes standard of care in oncology. And that decade has barely started.
This is not financial advice. Do your own due diligence. Natera carries real valuation and execution risk and should be sized accordingly within your portfolio.